Provided by Tiger Trade Technology Pte. Ltd.

Sunshine Biopharma Inc.

0.8030
+0.4051101.81%
Volume:153.53M
Turnover:162.92M
Market Cap:3.46M
PE:-0.08
High:1.54
Open:0.4095
Low:0.4000
Close:0.3979
52wk High:24.30
52wk Low:0.3564
Shares:4.31M
Float Shares:4.04M
Volume Ratio:149.33
T/O Rate:3798.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.0329
EPS(LYR):-14.3739
ROE:-21.92%
ROA:-9.91%
PB:0.13
PE(LYR):-0.06

Loading ...

US Stocks on the MOVE-Halozyme, Moderna, Merck

Reuters
·
22 mins ago

NASDAQ Trade Halt Volatility Trading Pause at 10:33 Am

Reuters
·
Yesterday

Sunshine Biopharma Shareholder Consent Authorizes Reverse Stock Split of up to 1-for-20

Reuters
·
Sep 28

Sunshine Biopharma launches generic Zofran in Canada

TIPRANKS
·
Sep 24

Sunshine Biopharma Files Draft Information Statement on Potential Reverse Stock Split up to 1-for-20

Reuters
·
Sep 17

Sunshine Biopharma - Board Authorized to Effect Reverse Split of Common Stock up to 1-for-20 - SEC Filing

THOMSON REUTERS
·
Sep 17

Sunshine Biopharma Inc: Advances Lead Coronavirus Drug Candidate into Ind-Enabling Studies

THOMSON REUTERS
·
Sep 16

Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies

Reuters
·
Sep 16

Sunshine Biopharma Cuts Warrant Exercise Price to 1.2

Reuters
·
Sep 12

Health Canada: Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions

THOMSON REUTERS
·
Aug 31

Health Canada Approves Sunshine Biopharma Atenolol Tablets for Canada Market

Reuters
·
Aug 31

Sunshine Biopharma Director Andrew Keller Declines to Seek Board Reelection

Reuters
·
Aug 29

Sunshine Biopharma provides update, outlines plans for oncology project

TIPRANKS
·
Aug 26

Sunshine Biopharma Wins Canadian Approval for Generic Enalapril Tablets

Reuters
·
Aug 19

Sunshine Biopharma: Enalapril Expected to Begin Shipping to Canadian Pharmacies by Year-End 2026

THOMSON REUTERS
·
Aug 19

Sunshine Biopharma: Receives Canadian Regulatory Approval for Enalapril

THOMSON REUTERS
·
Aug 19

Sunshine Biopharma Q2 Net Loss Narrows 11.67% to $1.56 Million; Revenue Slips 1.6% to $9.26 Million

Reuters
·
Aug 14

Sunshine announces approval of generic Dienogest tablets for Canadian market

TIPRANKS
·
Aug 04

Sunshine Biopharma Cuts Exercise Price of Outstanding Series B Warrants to $1.22

Reuters
·
Aug 03

Sunshine Biopharma Receives Health Canada Approval for Generic Ondansetron to Treat Chemotherapy-Induced Nausea

MT Newswires Live
·
Jul 28